TITLE

This week in BioWorld Asia

PUB. DATE
January 2014
SOURCE
BioWorld Today;1/2/2013, Vol. 25 Issue 1, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
A list of topics featured in the journal "BioWorld Asia" in January 2014 is presented including the plans of the Chinese government to relaunch its biopharmaceutical market, the privatization of Simcere Pharmaceutical Group, and the partnership of China's drug importer with BioCubaFarma.
ACCESSION #
93430880

 

Related Articles

  • Chinese Biopharmas Depart U.S. Markets to Escape Scandal. Schuster, Larry // BioWorld International;4/10/2013, Vol. 18 Issue 15, p3 

    The article discusses the delisting of a number of Chinese biopharmaceutical companies including Simcere Pharmaceutical Group, 3SBio Inc. and ShanghaPharma Corp., from the U.S.-based New York Stock Exchange owing to accounting scandals. It informs that scandals have tarnished the image of these...

  • PHARMA: OTHER NEWS TO NOTE.  // BioWorld Today;12/20/2013, Vol. 24 Issue 244, p2 

    This section offers news briefs in the biopharmaceutical industry in 2013. Pharmaceutical firm Daiichi Sankyo Co. Ltd. submitted application to the Japanese Ministry of Health, Labor and Welfare for the drug edoxaban. Simcere Pharmaceutical Group shareholders from China authorize the merger...

  • Cardiology Sector to Boom.  // Chain Drug Review;1/16/2012, Vol. 34 Issue 2, p61 

    The article offers various information related to cardiology in the U.S. including the U.S. Food and Drug Administration's (FDA's) approval to Edarbyclor, the expansion of the partnership between Simcere Pharmaceutical Group and Bristol-Myers Squibb Co., and prediction for anticoagualants' boost.

  • Simcere Pharmaceutical Receives $500M Proposal to Go Private. COLLINS, ALLISON // Mergers & Acquisitions Report;3/18/2013, Vol. 26 Issue 11, p4 

    The article reports on a 500 million U.S. dollars buyout offer received by Simcere Pharmaceutical Group from the chairman of its board of directors, Jinsheng Ren.

  • SIMCERE PHARMACEUTICAL AQUIRES 70% STAKE IN WUHU ZONG REN.  // Worldwide Biotech;Jun2008, Vol. 20 Issue 6, p8 

    This article reports on a definitive agreement signed by Simcere Pharmaceutical Group to acquire an equity interest in Wuhu Zhong Ren Pharmaceutical Co. This transaction is consistent with the strategy of Simcere to focus on first-to-market and innovative new drugs and expand its anti-cancer...

  • China's Heavyweight Pharma Goes Private, and into Biotech. Yang, Kristine // BioWorld International;9/11/2013, Vol. 18 Issue 37, p5 

    The article reports that the Simcere Pharmaceutical Group will transition into a private firm before the end of 2013. The company was initially a generic drug producer and has expanded into biological manufacturing. It share price crashed to below 5 U.S. dollars despite a favorable early...

  • Chinese Pharmas. Haddad, Anthony W. // Equities;Oct2009, Vol. 58 Issue 4, p50 

    The article presents information on four Chinese pharmaceutical firms in China including Wuxi Pharmatech Inc., Tongjitant Chinese Medicines Co. (TCM) and Simcere Pharmaceutical Group (SCR). Wuxi is a leading pharmaceutical firm in China that functions as an outsourcing company that focuses on...

  • Tigermed Cooperates with Simcere in Drugs R&D.  // China Chemical Reporter;12/26/2009, Vol. 20 Issue 36, p13 

    The article announces the partnership agreement signed by the leading Contract Research Organization (CRO) Tigermed Consulting Co. Ltd. and Jiangsu Simcere Pharmaceutical Group in China. It states that the agreement will see the two companies to collaborate in many aspects pertaining to medicine...

  • Chinese pharma industry eyes international opportunities.  // Global Processing;Jul2013, p5 

    The article discusses plans of big Chinese pharmaceutical companies to take advantage of the greater opportunities presented by global markets. Several expect to establish a presence in the U.S. mostly through partnerships with international industry giants. It cites Zhejiang Hisun...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics